Kabra drugs Limited has submitted its quarterly compliance certificate to BSE Limited, confirming adherence to SEBI regulations regarding dematerialization of securities for the quarter ended 31st March 2026. The pharmaceutical company filed the mandatory certificate pursuant to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Certificate Details

The certificate was issued by Skyline Financial Services Pvt Ltd, which serves as the company's Registrar and Share Transfer Agent. The document confirms that the company has properly handled the dematerialization process for physical share certificates received during the quarter.

Dematerialization Process Confirmation

The certificate confirms two critical compliance aspects for the dematerialization process:

• Securities Listing Verification: The securities comprised in the certificates have been properly listed on the stock exchange where the company's previously issued securities are traded
• Certificate Processing: Physical certificates have been duly verified, mutilated, and cancelled, with the depository's name substituted in records as the registered owner within the mandated 15-day timeframe

Corporate Information

Kabra Drugs Limited, incorporated under CIN L02423MP1989PLC005438, maintains its registered office at 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh. The compliance certificate was signed by Nanjappan Aravind, Managing Director (DIN: 02040505), and authenticated by Parveen Sharma, Authorised Signatory from Skyline Financial Services Private Limited.

Regulatory Significance

This quarterly filing represents standard regulatory compliance under SEBI's depositories framework, ensuring transparency in the conversion process from physical to electronic securities. The timely submission demonstrates the company's commitment to maintaining proper corporate governance standards and regulatory adherence in securities management.

Kabra Drugs Limited announced major corporate developments following its board meeting on March 07, 2026, including approval for a name change to Aanjaay Industries Limited and a strategic expansion into Indonesia's defence sector through a joint venture partnership.

Name Change Approval Received

The company received formal approval from the Ministry of Corporate Affairs on March 06, 2026, for changing its name from Kabra Drugs Limited to Aanjaay Industries Limited. The approval letter, issued by the Registrar of Companies at CRC Manesar, confirms there is no objection to the proposed name change.

The approval is subject to compliance with Section 4(2), 4(3) and other applicable provisions of the Companies Act, 2013. The name reservation remains valid for 60 days from the approval date and is liable to be withdrawn if found unsuitable before final approval.

Strategic Defence Partnership with Indonesia

The board approved a strategic expansion of business operations in Indonesia through a bilateral Strategic Comprehensive Joint Venture Agreement with PT. Bhinneka Dwi Persada Indonesia. This partnership focuses on defence technology development, engineering, and manufacturing of defence systems in India, along with participation in defence procurement programs and export of jointly developed defence systems.

Joint Venture Agreement Details

According to the regulatory disclosure, the collaboration aims to leverage the expertise and capabilities of both parties for development, manufacturing, procurement, and supply of strategic defence equipment and related technologies. Currently, Kabra Drugs Limited does not hold any shareholding in PT. Bhinneka Dwi Persada, though the parties may explore incorporating a joint venture entity subject to mutually agreed terms.

The agreement establishes strategic cooperation in the defence sector without providing PT. Bhinneka Dwi Persada any special rights such as director appointment rights, share subscription preferences, or restrictions on capital structure changes in Kabra Drugs Limited. The Indonesian partner is not related to the promoter, promoter group, or group companies of Kabra Drugs Limited, and the transaction does not fall within the ambit of related party transactions.

Corporate Governance and Compliance

The board meeting was conducted on March 07, 2026, from 05:00 p.m. to 06:30 p.m. IST, with Managing Director Nanjappan Aravind (DIN: 01895602) signing the regulatory disclosure. The announcement was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring full compliance with listing requirements.

This strategic expansion represents a significant shift for the company as it ventures into the defence technology sector while maintaining its commitment to supporting government initiatives and international partnerships. The name change to Aanjaay Industries Limited reflects the company's evolving business focus and strategic direction.